The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Crescent Biopharma Inc shares valued at $18,237,600 were purchased by Fairmount Funds Management LLC on Dec 04 ’25. At $13.41 per share, Fairmount Funds Management LLC acquired 1,360,000 shares. The insider’s holdings grew to 2,747,866 shares worth approximately $32.59 million following the completion of this transaction.
As published in their initiating research note from Jefferies on August 25, 2025, Crescent Biopharma Inc [CBIO] has been a Buy and the price target has been revised to $26. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in mid August. As of July 14, 2025, Wedbush has initiated its “an Outperform” rating for CBIO. Earlier on June 25, 2025, Stifel initiated its rating. Their recommendation was “a Buy” for CBIO stock.
Analyzing CBIO Stock Performance
On last trading session, Crescent Biopharma Inc [NASDAQ: CBIO] rose 2.24% to $11.86. The stock’s lowest price that day was $11.4, but it reached a high of $11.9 in the same session. During the last five days, there has been a drop of approximately -2.15%. Over the course of the year, Crescent Biopharma Inc shares have dropped approximately -49.83%. Shares of the company reached a 52-week high of $37.00 on 02/18/25 and a 52-week low of $9.81 on 10/14/25.
Support And Resistance Levels for Crescent Biopharma Inc (CBIO)
According to the 24-hour chart, there is a support level at 11.54, which, if violated, would cause prices to drop to 11.22. In the upper region, resistance lies at 12.04. The next price resistance is at 12.22. RSI (Relative Strength Index) is 41.07 on the 14-day chart, showing neutral technical sentiment.
Is Crescent Biopharma Inc subject to short interest?
Stocks of Crescent Biopharma Inc saw a sharp rise in short interest on 2025-12-15 jumping by 0.21 million shares to 0.79 million. Data from Yahoo Finance shows that the short interest on 2025-11-14 was 0.58 million shares. A jump of 26.87% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.76 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.76.
Which companies own the most shares of Crescent Biopharma Inc (CBIO)?
In terms of Crescent Biopharma Inc share price expectations, FactSet research, analysts set an average price target of 29 in the next 12 months, up nearly 150.0% from the previous closing price of $11.6. Analysts anticipate Crescent Biopharma Inc stock to reach 32 by 2026, with the lowest price target being 26. In spite of this, 1 analysts ranked Crescent Biopharma Inc stock as Hold at the end of 2026.
